• LAST PRICE
    0.0500
  • TODAY'S CHANGE (%)
    Trending Down-0.0020 (-3.8462%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0470 / 0.0520
  • Day Range
    Low 0.0450
    High 0.0500
  • 52 Week Range
    Low 0.0450
    High 0.9000
  • Volume
    5,966
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.052
TimeVolumeBTAX
10:51 ET40000.048
11:56 ET16000.0488
12:33 ET1000.04499
01:51 ET2650.05
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBTAX
Biostax Corp
4.2M
-2.6x
---
United StatesSNPX
Synaptogenix Inc
4.2M
-0.2x
---
United StatesVRPX
Virpax Pharmaceuticals Inc
4.1M
-0.3x
---
United StatesONCO
Onconetix Inc
4.1M
-0.2x
---
United StatesKTRA
Kintara Therapeutics Inc
3.9M
0.0x
---
United StatesPTIX
Protagenic Therapeutics Inc
4.4M
-1.1x
---
As of 2024-03-03

Company Information

Biostax Corp., formerly Immune Therapeutics, Inc., is a biopharmaceutical company that acquires and develops immune restoration pharmaceutical and medical technology (MedTech) products with a well -defined path to market. Biostax has partnerships in the fields of autoimmunity and immune restoration, which focuses on delivering solutions for people living with autoimmunity, chronic inflammation, infection, and cancer. Its subsidiary BiostaxRx, is focused on the treatment of inflammaging disease. Its product portfolio includes Londonal, JKB-122 and Low Dose Naltrexone. Lodonal is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). JKB-122 is a therapy developed for the purposes of treating Autoimmune Hepatitis (AIH), Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that shows anti-fibrotic, immune modulating, and/or anti-inflammatory effects.

Contact Information

Headquarters
2431 Aloma Ave #124WINTER PARK, FL, United States 32792
Phone
407-680-3097
Fax
407-641-8668

Executives

President
Kelly Wilson
Chief Executive Officer
Noreen Griffin
Chief Financial Officer
Glen Farmer
Secretary
Cynthia Douglas
Director
Mary Caperton

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.2M
Revenue (TTM)
$0.00
Shares Outstanding
83.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.02
EPS
$-0.02
Book Value
$-0.03
P/E Ratio
-2.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.